

December 3, 2014

Dear Colleagues:

Your EAP liaison group continues to meet quarterly with the directors and managers at the Exceptional Access Program to ensure that criteria and processes meet current standards of care, best practices and efficiency. We are pleased to announce to our membership the following changes to the ADULT Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriatic Spondylitis Criteria. For those patients who have continued success with a biologic agent, then a 5 year renewal has been approved for the 2nd or later RENEWAL. (i.e. (i.e. initial 1 year APPROVAL, first RENEWAL 1 year, 2nd RENEWAL and afterwards 5 years) Please refer to chart below.

Sincerely,



Dr. Arthur Karasik, ORA President, for the EAP Committee

EAP Committee Members: Dr Arthur Karasik, Dr. Carter Thorne, Dr. Jane Purvis, Dr. Angela Montgomery, Dr. Deb Levy, Mr. Denis Morrice.



Enbrel Humira Remicade Simponi Cimzia Orencia Kineret Actemra	Rheumatoid Arthritis	5 years for 2+ renewals from the current 2 years
Enbrel Humira Remicade Simponi	Ankylosing Spondylitis or Psoriatic Spondylitis	5 years for 2+ renewals from the current 2 years
Enbrel Humira Simponi	Psoriatic Arthritis	5 years for 2+ renewals from the current 2 years